Caroline Baumal Sells 2,816 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Caroline Baumal sold 2,816 shares of Apellis Pharmaceuticals stock in a transaction on Monday, January 6th. The stock was sold at an average price of $33.81, for a total transaction of $95,208.96. Following the sale, the insider now directly owns 55,560 shares in the company, valued at $1,878,483.60. This trade represents a 4.82 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Apellis Pharmaceuticals Trading Down 4.7 %

Shares of NASDAQ APLS opened at $33.00 on Friday. The company has a market cap of $4.10 billion, a price-to-earnings ratio of -16.26 and a beta of 0.94. The stock’s 50 day simple moving average is $31.76 and its 200 day simple moving average is $33.82. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a 12-month low of $24.34 and a 12-month high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The firm had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm’s revenue was up 78.3% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.17) EPS. Equities research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.72 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on APLS shares. Scotiabank cut their price target on Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a research note on Wednesday, November 6th. JPMorgan Chase & Co. reduced their target price on Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating for the company in a research note on Friday, September 13th. Piper Sandler dropped their price target on shares of Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating for the company in a research note on Wednesday, November 6th. HC Wainwright reduced their price objective on shares of Apellis Pharmaceuticals from $83.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Finally, The Goldman Sachs Group downgraded shares of Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 target price for the company. in a research report on Tuesday, December 17th. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $49.94.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several large investors have recently made changes to their positions in APLS. Wolverine Asset Management LLC acquired a new position in shares of Apellis Pharmaceuticals during the third quarter worth approximately $27,000. True Wealth Design LLC acquired a new position in Apellis Pharmaceuticals during the 3rd quarter worth $27,000. Capital Performance Advisors LLP bought a new position in shares of Apellis Pharmaceuticals in the third quarter worth $56,000. KBC Group NV raised its stake in shares of Apellis Pharmaceuticals by 34.8% during the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after purchasing an additional 679 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after purchasing an additional 781 shares during the period. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).